WASHINGTON, Aug. 30 /PRNewswire/ -- United BioSource Corp. (UBC), formed in 2003 to provide scientific and information-based product development and commercialization services to the pharmaceutical and life sciences industries, today announced the acquisition of B&B Clinical Innovations, Inc., (BBCI) a leading provider of late-stage clinical development services for pharmaceutical companies. The addition of BBCI is the latest in a series of acquisitions announced since the Washington-based UBC raised $153 million in equity capital from a syndicate of leading private equity firms.
BBCI is a privately held contract research organization (CRO) with clinical development operations in North and South America and throughout Europe. With experience in every major therapeutic category, BBCI is the only CRO focused specifically on late-stage drug development, including post- marketing studies, product life-cycle management, risk management, and patient registries.
Since 1976, BBCI has participated in the design and implementation of more than 2,750 clinical protocols and has provided clinical support for more than 150 new drug applications and over-the-counter products. During the past few years, BBCI has managed late-stage studies utilizing over 27,000 investigator sites that enrolled over 100,000 patients into study databases.
"We are proud to welcome BBCI to our team," said UBC Founder and CEO Ethan Leder. "With this acquisition, UBC offers clients an unprecedented combination of scale and specialization to meet the growing demand for late- stage clinical development and commercialization services."
BBCI will operate as a wholly owned subsidiary of UBC. The BBCI executive management team will continue in their current leadership roles within the company. BBCI will remain headquartered in Kansas City, Mo.
"With the support of UBC and their specialized service offerings, we expect to achieve our goal of becoming the dominant, international provider of late stage clinical development services in the industry," said BBCI CEO Sean Hart.
Since the beginning of 2004, UBC has assembled a broad array of industry- leading late-stage scientific and information capabilities. Ten UBC offices throughout North America and Europe are fully dedicated to the development and execution of late-stage product development and commercialization services.
BBCI is a contract research organization dedicated to providing late-stage clinical development services to the pharmaceutical and biotechnology industries. Since 1976, the company has specialized in the development and execution of clinical studies and risk-management programs to support pharmaceutical products. For more information about BBCI, go to http://www.bbclinical.com/ or call 1-800-366-8531.
United BioSource Corporation (UBC) was formed in 2003 to provide scientific and information-based services to the pharmaceutical and life sciences industries. For more information about UBC, visit http://www.unitedbiosource.com/ or call 202-457-1900.
United BioSource Corporation